Ribophorin II Overexpression Is Associated with Poor Response to Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in P16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma

• Main Authors: Wei-Shan Chen, Sheng-Dean Luo, Tai-Jan Chiu, Yu-Ming Wang, Wei-Chih Chen, Chih-Yen Chien, Fu-Min Fang, Tai-Lin Huang, Shau-Hsuan Li
• Format: Article
• Language: English
• Published: MDPI AG 2021-09-01
• Series: Journal of Clinical Medicine
• Subjects: head and neck cancer; ribophorin II (RPN2); induction chemotherapy
• Online Access: https://www.mdpi.com/2077-0383/10/18/4118
• ISSN: 2077-0383

This study aims to evaluate the relationship between human ribophorin II (<i>RPN2</i>) and the effect of treatment using induction therapy with docetaxel, cisplatin, and fluorouracil (TPF) for <i>p</i>-16 negative locally advanced head and neck squamous cell carcinoma (HNSCC). A total of 203 patients with locally advanced p-16 negative HNSCC who received induction chemotherapy with TPF at the Kaohsiung Chang Gung Memorial Hospital between 2009 and 2014 were enrolled. Immunohistochemistry (IHC) for RPN2 was examined and correlated with treatment outcome. Our study showed that RPN2 overexpression was significantly correlated with a poor response to induction chemotherapy with TPF. Both RPN2 overexpression and clinical N1 to N3 stages represented adverse prognostic factors for progression-free survival (PFS) and overall survival (OS). RPN2 might be a predictive marker for treatment response to induction chemotherapy. Further clinical trials are needed to determine the therapeutic significance of RPN2 in patients with HNSCC.